US EditionStudy Reveals Tumor Defense Mechanisms in Colorectal Cancer
The hormone TGF-β prevents T lymphocyte infiltration and expansion in colorectal tumors, creating a dual immune barrier that limits immunotherapy effectiveness, researchers found.
10 Articles
10 Articles
Study reveals tumor defense mechanisms in colorectal cancer
Colorectal cancer is one of the leading causes of cancer death worldwide. In recent years, immunotherapies-treatments that reactivate the immune system to attack tumor cells-have transformed the treatment of many types of cancer.
How colorectal cancer evades immunotherapy using a dual barrier
Colorectal cancer is one of the leading causes of cancer death worldwide. In recent years, immunotherapies—treatments that reactivate the immune system to attack tumor cells—have transformed the treatment of many types of cancer. However, most patients with metastatic colorectal cancer do not respond to these treatments.
Metastatic Colorectal Cancer Blocks Immunotherapy with Dual Barrier
Researchers in Barcelona have identified a previously unknown mechanism that metastatic colorectal cancer employs to evade immune checkpoint immunotherapy. A study published today in Nature Genetics reveals how these tumors use the transforming growth factor beta (TGF-β) cytokine to activate a dual barrier that blocks the immune system’s response. “Our work shows that tumors defend themselves against immunotherapies by manipulating their enviro…
A study led by the Instituto de Investigación Biomédica (IRB Barcelona) and the National Center for Genomic Analysis (CNAG) has found that metastatic colorectal tumors are protected from immunotherapy through two complementary mechanisms that exert double shield blocking the immune system. Research, published in Nature Genetics, identifies osteopontin as a key protein responsible for stopping the action of defensive cells within the tumor, accor…
Tumors activate a dual mechanism to evade the action of our defenses
A study by the Instituto de Investigación Biomédica (IRB Barcelona) and the National Centre for Genomic Analysis (CNAG) has revealed that, through a hormone called TGF-B, colorectal tumors create a double barrier that prevents the action of the immune system and therefore immunotherapy.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
